Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DRibble Vaccine with DC-CIK in Advanced Lung Cancer
NCT03057340Phase 1Unknown
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Jun 2017
- Primary completion
- Dec 2019
- Modality
- Whole Cell Cancer Vaccines, Oncolytic Viruses, Dendritic Cell Vaccines
01
Overview
Phase 1, randomised, open-label trial of DPV-001 in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Progression Free Survival at 2 years. Status: unknown.
02
Drugs
DPV-001
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03057340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03057340.